Evidence map›Paper›PMID 41567834›Full record

ReviewAmerican journal of nuclear medicine and molecular imaging2025

Current landscape and clinical progress of targeted alpha radioimmunotherapy.

Owen C Booth, Karena R Dhamecha, Oluwaseyi M Oderinde, Qi-Huang Zheng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Owen C BoothDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine Indianapolis, IN, USA.
Karena R DhamechaDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine Indianapolis, IN, USA.
Oluwaseyi M OderindeDepartment of Radiation Oncology, Indiana University School of Medicine Indianapolis, IN, USA.
Qi-Huang ZhengDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine Indianapolis, IN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Theranostics is an interesting area of cancer research that describes the use of radiotracers to first diagnose and then treat cancer. By coupling a radioisotope to an agent that selectively targets malignant cells, one can distribute focused radiation to disease sites. There are a variety of different radiopharmaceutical vectors that have been utilized in this way, such as peptides, small molecules and antibodies. Because antibodies bind to highly specific antigens, radioimmunotherapy (RIT) offers a promising route to precisely targeted treatments with reduced systemic toxicity compared to conventional radiotherapy. Beta (β)-emitting isotopes (e.g.,

Indexed as

Alpha radioimmunotherapy (α-RIT)hematologic malignanciesmonoclonal antibodies (mAbs)prostate cancersolid tumorsα-emitting radionuclides

Identifiers

PMID41567834
PMCPMC12816825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.